Update shared on 11 Dec 2025
Fair value Decreased 0.27%Analysts have nudged their price target on Ansell slightly lower to about A$37 from roughly A$37.10, reflecting only minor model adjustments. They continue to view the stock as undervalued given that its current discount appears larger than the potential impact of tariffs on healthcare personal protective equipment.
Analyst Commentary
Bullish Takeaways
- Bullish analysts highlight that the unchanged A$39 price target, despite no changes to forecasts, implies meaningful upside from current levels based purely on valuation.
- They argue that the stock screens as inexpensive relative to its earnings and cash flow potential, with the current discount seen as disproportionate to tariff related risks.
- Positive views emphasize management’s ability to execute on margin improvement and cost controls, which could unlock additional earnings leverage if demand conditions stabilize.
- Bullish analysts see limited downside from here, contending that much of the macro and regulatory uncertainty is already reflected in the share price.
Bearish Takeaways
- Bearish analysts remain cautious that any escalation or broadening of healthcare tariff regimes could compress margins more than currently modeled, challenging the valuation case.
- They flag execution risks around sustaining recent operational improvements, noting that any missteps in cost management could quickly erode the perceived discount.
- Some remain wary that slower than expected volume growth in healthcare personal protective equipment could cap near term earnings momentum and delay a re rating.
- Bearish analysts also point to broader sector volatility and regulatory overhangs, which could keep the stock trading at a discount to historical multiples for longer.
What's in the News
- Opened its first Ansell Xperience & Innovation Studio (AXIS) in Alpharetta, Georgia, providing an immersive, collaborative environment focused on advanced safety education, live product testing, and co creation of protective solutions (Key Developments).
- Positioned AXIS as a strategic response to rapidly evolving safety needs, using expert led education and real world hazard simulations to help customers navigate new technologies and shifting industry standards (Key Developments).
- Announced plans for a second AXIS location in Coimbra, Portugal next year, extending the global footprint of its innovation and training capabilities (Key Developments).
- Confirmed AXIS access is by invitation via Ansell representatives or distributors, underlining its role as a partnership driven platform for high impact safety innovation (Key Developments).
Valuation Changes
- Fair Value Estimate has edged down slightly to about A$36.97 from roughly A$37.07, reflecting minimal model revisions.
- Discount Rate has fallen marginally to approximately 7.76% from about 7.78%, indicating a slightly lower assumed risk profile.
- Revenue Growth has risen slightly to around 4.98% from roughly 4.93%, suggesting a modestly more optimistic top line outlook.
- Net Profit Margin has improved fractionally to about 10.21% from around 10.20%, pointing to a small uplift in expected profitability.
- Future P/E multiple has increased modestly to roughly 18.80x from about 18.46x, implying a slightly higher valuation on forecast earnings.
Have other thoughts on Ansell?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
